Related Experiment Video
Updated: Mar 1, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Modified rifampin nanoparticles: Increased solubility with slow release Rate
Poopak Farnia1, Ali Akbar Velayati2, Saeed Mollaei3
1Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease, (NRITLD), Shahid Beheshti University of Medical Sciences; Department of Biotechnology, School of Advanced Technology in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Background:
Recent advances in nanotechnology-based drug delivery system have been shown to improve either antibacterial efficacy or pharmacokinetics behavior.The aim of this study was to design a rifampin nanoparticle (RIF-NP) which has a high loading capacity with the slow release profile.
Material And Methods:
The designed chitosan/gelatin/lecithin (Chg/L) RIF-NPs were prepared by multilamellar vesicle. Thereafter, the particle size, zeta potential, morphology, and release rate were investigated. To optimize the loading capacity and release profiles, different concentrations of lecithin were used.
Results:
Our results showed a correlation of lecithin concentration with size, zeta potential, and loading capacity of RIF-NPs. Increases in lecithin concentration (0.2-2.0 g) could cause a significant size reduction in NPs (250-150 nm); the amount of zeta potential (from 14 to 49 mV;P < 0.05) and loading capacity increases from 8% to 20% (P < 0.05). Designed NPs had slow drug release profile which was influenced by pH and lecithin concentration. The cumulative percentage of RIF released at pH 7.4 was approximately 93% up to 12 h. In overall, release profile was better than standard drug, even in various pH conditions (pH = 1, 3.4, and 7.4). The Chg/L-RIF NPs may be considered as a promising drug nanocarrier.
Conclusions:
These NPs release RIF in slow and constant rate, which effectively might eliminate the bacilli and prevent the formation of RIF-resistant bacilli.
Related Concept Videos
Bioavailability Enhancement: Drug Solubility Enhancement
Modified-Release Drug Delivery Systems: Influencing Factors
Modified-Release Drug Delivery Systems: Bioavailability
Factors Affecting Dissolution: Particle Size and Effective Surface Area
Modified-Release Drug Delivery Systems: Rate-Programmed I
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

